Table 3.
Ref. | Sample (positive vs negative) | Patients who died in 5 yr (positive vs negative) | P value |
Cai et al[18], 2000 | 69 (17 vs 52) | 3/17 vs 0/52 | < 0.01 |
Fukagawa et al[19], 2001 | 107 (38 vs 69) | 2/38 vs 8/69 | 0.860 |
Choi et al[20], 2002 | 88 (28 vs 60) | 2/28 vs 3/60 | 0.683 |
Lee et al[21], 2002 | 153 (75 vs 78) | Total: 38/75 vs 19/78; EGC: 2/12 vs 0/34; AGC: 36/63 vs 19/44 | < 0.05 |
Yasuda et al[22], 2002 | 64 (20 vs 44) | 7/20 vs 2/44 | < 0.1 |
Morgagni et al[23], 2003 | 300 (30 vs 270) | 2/30 vs 30/270 | 0.779 |
Yonemura et al[24], 2007 | 308 (37 vs 271) | 5/37 vs 16/271 | 0.014 |
Kim et al[25], 2008 | 184 (31 vs 153) | 13/31 vs 13/1531 | < 0.001 |
Ishii et al[26], 2008 | 35 (4 vs 31) | - | - |
Kim et al[27], 2009 | 90 (9 vs 81) | 0/9 vs 0/812 | - |
Wang et al[28], 2011 | 191 (54 vs 137) | 39/54 vs 18/137 | < 0.001 |
Jeuck et al[29], 2014 | 95 (16 vs 79) | 6/16 vs 21/79 | 0.026 |
Median survival 17 mo, 95%CI: 7-28 for micrometastasis positive, and median survival not reached, 95%CI: 6-121 mo for micrometastasis negative;
Disease-specific survival. EGC: Early gastric cancer; AGC: Advanced gastric cancer.